SMO S278I

CI-VAR-00004044Explore in graph →CIViC 1562

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Basal Cell Carcinoma1
SMO S278I	Vismodegib	Predictive	C	Supports Resistance	—	submitted	EID4636 In a retrospective study of 15 vismodegib-resistant basal cell carcinoma (BCC) patients, a BCC patient harboring SMO S278I mutation was reported to be resistant to vismodegib monotherapy. PMID 25759020 · Atwood et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.